08:56 AM EDT, 09/08/2025 (MT Newswires) -- Guardant Health ( GH ) said Monday it has partnered with PathGroup to expand access to its US Food and Drug Administration-approved Shield blood test for colorectal cancer screening.

The partnership will bring Shield to more than 250 hospitals and health systems, over 15,000 physicians in 25 states, and millions of patients tested annually through PathGroup, the company said.

The company will integrate Shield into its electronic ordering systems, allowing providers to adopt the test within their existing workflows, Guardant said.

Shield is the first blood test approved by the FDA as a primary screening option for colorectal cancer, which has a 91% five-year survival rate if detected early, the company added.